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Pembrolizumab, a checkpoint inhibitor, has improved 
the prognosis of advanced malignancies such as malig-
nant melanoma [1]. Programmed cell death protein 1 
(PD-1) is a negative regulator of T-cell activation, gener-
ally expressed on chronically activated T cells, especially 
CD8+ T cells [2]. PD-1 inhibitors like pembrolizumab 
prevent programmed death-ligand 1 (PD-L1) expressed 
by tumour cells from binding to PD-1 on the T cells. This 
restores the T-cell antitumor response resulting in tumour 
apoptosis. However, it is a double-edged sword resulting 
in endocrinopathies such as hypophysitis, thyroiditis, and 
rarely new-onset diabetes. The pancreas also expresses 
PD-L1, and PD-1 inhibitors can result in the T cells medi-
ating an immune response against the beta cells, resulting 
in cell destruction and acute onset insulin deficiency [2, 3]. 
We report a case of 83-year-old Caucasian female who 
presented with rapid onset of lethargy, polyuria, and 
polydipsia over the preceding three days. She was 
treated with Pembrolizumab (seven cycles given: first 
cycle given 23 weeks ago) following a diagnosis of 
metastatic melanoma. She had no pre-existing history 
of diabetes mellitus and had normal capillary blood 
glucose levels three weeks prior to admission.  
On examination, she had dry mucous membranes 
with a heart rate of 104 beats per minute, blood pressure 
was 164/100 mm Hg, oxygen saturations were 99% on 
room air, respiratory rate 14 breaths per minute, and 
temperature 37°C. Chest, abdominal, and cardiovas-
cular examinations were unremarkable. 
The venous blood gas demonstrated pH — 7.37 
(7.35–7.45), bicarbonate — 23.7 mmol/L (22–28), lactate 
— 2.5 mmol/L (0–2), blood glucose  — 35.1 mmol/L, and 
blood ketones  — 2.2 mmol/L. Laboratory investigations 
are shown in Table 1. Serum C-peptide (244 pmol/L) was 
low for glucose value. CT pancreas was unremarkable. 
She was initially treated with a variable-rate insulin 
infusion. Subsequently, she was started on a basal-bolus 
insulin regimen. She was diagnosed with pembrolizum-
ab-induced diabetes. 
Pembrolizumab was restarted once her blood glu-
cose was stable. After 10 months her urine C-peptide 
was 0.09 nmol/L and the urine C-peptide/creatinine ra-
tio was 0.02 nmol/mmol, in keeping with severe insulin 
deficiency. The patient remains stable on basal-bolus 
insulin therapy with HbA1c of 66 mmol/mol (8.2%).
Pembrolizumab-induced diabetes is a serious, albeit 
rare, adverse effect of pembrolizumab. The reported 
incidence is 0.2% [4], with 43 cases reported in the 
literature, the majority of patients having malignant 
melanoma. 
Patients may present with osmotic symptoms 
including polydipsia or polyuria, non-specific symp-
toms such as headaches and vomiting, or they may be 
asymptomatic. The onset of diabetes was variable in the 
literature, with the majority of patients presenting be-
tween 3 and 20 weeks of starting pembrolizumab. Our 
case presented at 23 weeks of starting pembrolizumab. 
The most common findings are elevated blood 
glucose levels, elevated ketones, mildly elevated HbA1c 
(< 75 mmol/mol, 9%), and reduced C-peptide levels 
[4]. C-peptide has a better discriminative value if the 
test is done sometime after the diagnosis. Therefore, 
a normal/elevated level at presentation does not exclude 
the presence of insulin deficiency. In our case, serum 
C-peptide at presentation was low for glucose levels. In 
addition, it took a few months before urine C-peptide 
levels demonstrated severe insulin deficiency. 
Whilst most cases in the literature present with 
diabetic ketoacidosis, diabetes autoantibodies are often 
absent at diagnosis, in keeping with acute beta-cell de-
struction4. In our case, antibodies were absent. Several 
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studies have reported mild elevations of serum amylase 
and serum lipase, without features of pancreatitis on 
imaging, although pancreatic atrophy may be seen [5, 6].
With the increasing use of check-point inhibitors 
like pembrolizumab, it is important to consider this 
diagnosis in all patients on pembrolizumab present-
ing with new-onset diabetes, and not discharge these 
patients from the emergency department with oral 
hypoglycaemic agents without specialist input. Patients 
invariably need long-term insulin treatment due to 
pancreatic failure.
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tables 1. Laboratory values at the time admission
Blood test Value (normal range)
Haemoglobin [g/L] 133 (115–165)
White cells [× 109/L] 10.2 (4–10)
Platelets [× 109/L] 393 (150–410)
Urea [mmol/L] 5.0 (2.7–5)
Sodium [mmol/L] 126 (136–145)
Potassium [mmol/L] 4.9 (3.5–5.1)
Creatinine [µmol/L] 72 (62–106)
Alanine aminotransferase [IU/L] 8 (0–33)
Alkaline phosphatase [IU/L] 87 (35–104)
Bilirubin [µmol/L] 6 (0–21)
Amylase [U/L] 47 (28–100)
C-reactive protein [mg/L] 24 (0–5)
Thyroid stimulating hormone [mU/L] 1.07 (0.27–4.2)
Free thyroxine [pmol/L] 19.2 (12–22)
Follicle-stimulating hormone [IU/L] 64.3 (3.5–12.5)
Luteinizing hormone [IU/L] 14.8 (2.4–12.6)
9 am cortisol [nmol/L] 594 (>285)
Prolactin [mIU/L] 202 (102–496)
Glycated haemoglobin [mmol/mol] 76 (0–42)
Glucose [mmol/L] 35.1 (3.2–11.1)
Measured serum osmolality  
[mOsm/kg] 292 (285–295)
Urine C-peptide [nmol/L]* 1.81
Urine C-peptide/creatinine ratio  
[nmol/mmol]* 0.65 (> 0.6)
Serum GAD-65 antibodies Negative
Serum IA2 antibodies Negative
Serum zine transporter 8 antibodies Negative
